A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain : combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials
Garcia-Moll, Xavier (Institut de Recerca Sant Pau)
Croci, F. (EMEA Real World Methods & Evidence Generation. IQVIA)
Solé, A. (Boehringer Ingelheim España)
Hartgers-Gubbels, E.S. (Boehringer Ingelheim International GmbH)
Calleja Hernández, Miguel Ángel (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background: Heart failure (HF) is a chronic condition with considerable clinical burden for patients and economic burden for healthcare systems. Treatment for HF is typically based on ejection fraction (EF) phenotype. The cost-effectiveness of empagliflozin + standard of care (SoC) compared to SoC has been examined for HF phenotypes below or above 40% EF separately, but not across the full spectrum of EF in Spain. Methods: The results of two preexisting, validated, and published phenotype-specific Markov cohort models were combined using a population-weighted approach, reflecting the incidence of each phenotype in the total HF population in Spain. A probabilistic sensitivity analysis was performed by sampling each model's probabilistic results. Results: Empagliflozin + SoC compared to SoC resulted in increased life-years (LYs) (6. 48 vs. 6. 35), quality-adjusted LYs (QALYs) (4. 80 vs. 4. 63), and healthcare costs (€19,090 vs. €18,246), over a lifetime time horizon for the combined HF population in Spain. The incremental cost-effectiveness ratio (ICER) was €5,089/QALY. All subgroup, scenario, and probabilistic ICERs were consistently below €10,000/QALY. Conclusions: Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cost-effectiveness ; SGLT inhibitors ; Spain ; Ejection fraction ; Empagliflozin ; Heart failure
Publicat a:	Expert Review of Cardiovascular Therapy, Vol. 22 Núm. 1-3 (2024) , p. 131-139, ISSN 1744-8344

DOI: 10.1080/14779072.2024.2324027
PMID: 38416135

10 p, 2.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats